Leerink Partnrs Issues Optimistic Forecast for RCKT Earnings

Key Points

• Analysts at Leerink Partners raised their Q3 2025 EPS estimate for Rocket Pharmaceuticals to ($0.49) from a previous forecast of ($0.54), while maintaining a "Hold" rating.
• The company's current full-year earnings estimate is projected at ($2.83) per share, with future forecasts estimating similar losses through 2027.
• Institutional investors own 98.39% of Rocket Pharmaceuticals stock, indicating strong backing from major financial entities in the company.

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) - Equities research analysts at Leerink Partnrs raised their Q3 2025 earnings per share estimates for Rocket Pharmaceuticals in a report released on Wednesday, July 23rd. Leerink Partnrs analyst M. Foroohar now anticipates that the biotechnology company will earn ($0.49) per share for the quarter, up from their prior estimate of ($0.54). Leerink Partnrs has a "Hold" rating on the stock. The consensus estimate for Rocket Pharmaceuticals' current full-year earnings is ($2.83) per share. Leerink Partnrs also issued estimates for Rocket Pharmaceuticals' Q4 2025 earnings at ($0.41) EPS, FY2025 earnings at ($2.03) EPS, FY2026 earnings at ($2.13) EPS and FY2027 earnings at ($1.93) EPS.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.02. During the same period last year, the company posted ($0.66) EPS.

Several other equities research analysts also recently issued reports on RCKT. Cantor Fitzgerald raised their price objective on shares of Rocket Pharmaceuticals from $20.00 to $30.00 and gave the stock an "overweight" rating in a research note on Friday, May 16th. Chardan Capital reduced their target price on Rocket Pharmaceuticals from $17.00 to $12.00 and set a "buy" rating for the company in a research report on Thursday, July 24th. Jefferies Financial Group reaffirmed a "hold" rating on shares of Rocket Pharmaceuticals in a research report on Wednesday, May 28th. Leerink Partners reaffirmed a "market perform" rating and issued a $8.00 target price (down from $37.00) on shares of Rocket Pharmaceuticals in a research report on Wednesday, May 28th. Finally, JPMorgan Chase & Co. reaffirmed a "neutral" rating on shares of Rocket Pharmaceuticals in a research report on Wednesday, May 28th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat, Rocket Pharmaceuticals currently has an average rating of "Hold" and an average price target of $17.87.

Rocket Pharmaceuticals Stock Performance

Shares of Rocket Pharmaceuticals stock traded down $0.05 during midday trading on Monday, hitting $3.10. The company had a trading volume of 362,310 shares, compared to its average volume of 3,409,439. The business's 50 day simple moving average is $3.17 and its two-hundred day simple moving average is $6.55. The stock has a market cap of $330.52 million, a PE ratio of -1.18 and a beta of 0.67. The company has a debt-to-equity ratio of 0.05, a current ratio of 9.19 and a quick ratio of 9.19. Rocket Pharmaceuticals has a 1-year low of $2.19 and a 1-year high of $24.74.

Hedge Funds Weigh In On Rocket Pharmaceuticals

Several institutional investors have recently modified their holdings of RCKT. Covestor Ltd lifted its holdings in shares of Rocket Pharmaceuticals by 33,166.7% during the 4th quarter. Covestor Ltd now owns 1,996 shares of the biotechnology company's stock valued at $25,000 after purchasing an additional 1,990 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in Rocket Pharmaceuticals by 7,818.1% in the 2nd quarter. Farther Finance Advisors LLC now owns 13,540 shares of the biotechnology company's stock valued at $33,000 after acquiring an additional 13,369 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Rocket Pharmaceuticals in the 2nd quarter valued at approximately $43,000. PFG Investments LLC lifted its stake in Rocket Pharmaceuticals by 35.1% in the 2nd quarter. PFG Investments LLC now owns 18,100 shares of the biotechnology company's stock valued at $44,000 after acquiring an additional 4,700 shares in the last quarter. Finally, 111 Capital bought a new stake in Rocket Pharmaceuticals in the 2nd quarter valued at approximately $55,000. 98.39% of the stock is currently owned by institutional investors and hedge funds.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.